David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Cambridge Quarterly of Healthcare Ethics 18 (01):78- (2008)
|Abstract||This article has no associated abstract. (fix it)|
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Jennifer Radden (2012). Recognition Rights, Mental Health Consumers and Reconstructive Cultural Semantics. Philosophy, Ethics, and Humanities in Medicine 7 (1):1-8.
Fenella Corrick, Robert Watson & Sanjay Budhdeo (2011). Should Patents for Antiretrovirals Be Waived in the Developing World? Annual Varsity Medical Debate - London, 21 January 2011. Philosophy, Ethics, and Humanities in Medicine 6 (1):1-6.
Doris Schroeder & Peter Singer (2011). Access to Life-Saving Medicines and Intellectual Property Rights: An Ethical Assessment. Cambridge Quarterly of Healthcare Ethics 20 (2):279-289.
Tikki Pang (2011). Developing Medicines in Line with Global Public Health Needs: The Role of the World Health Organization. Cambridge Quarterly of Healthcare Ethics 20 (2):290-297.
Similar books and articles
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
Aidan Hollis (2008). The Health Impact Fund: A Useful Supplement to the Patent System? Public Health Ethics 1 (2):124-133.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Meri Koivusalo (2010). Common Health Policy Interests and the Shaping of Global Pharmaceutical Policies. Ethics and International Affairs 24 (4):395-414.
Joo-Young Lee & Paul Hunt (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. Journal of Law, Medicine and Ethics 40 (2):220-233.
M. Peterson, A. Hollis & T. Pogge (2010). A Critique in Need of Critique. Public Health Ethics 3 (2):178-185.
Thomas Pogge (2009). The Health Impact Fund and its Justification by Appeal to Human Rights. Journal of Social Philosophy 40 (4):542-569.
V. Paivansalo (2009). Responsibilities for Global Health: The Efficiency of the Health Impact Fund? Public Health Ethics 2 (1):100-104.
Frank R. Lichtenberg (2005). Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries. Journal of Medicine and Philosophy 30 (6):663 – 690.
Ashish Chandra & Gary A. Holt (1999). Pharmaceutical Advertisements: How They Deceive Patients. [REVIEW] Journal of Business Ethics 18 (4):359 - 366.
Ville Päivänsalo (2009). Responsibilities for Global Health: The Efficiency of the Health Impact Fund? Public Health Ethics 2 (1):100-104.
Thomas Alured Faunce & Hitoshi Nasu (2008). Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty. Public Health Ethics 1 (2):146-153.
Alex Rajczi (2007). A Critique of the Innovation Argument Against a National Health Program. Bioethics 21 (6):316–323.
Morgan P. Miles, Linda S. Munilla & Jeffrey G. Covin (2002). The Constant Gardener Revisited: The Effect Ofsocial Blackmail on the Marketing Concept,Innovation, and Entrepreneurship. [REVIEW] Journal of Business Ethics 41 (3):287 - 295.
Nicholas Capaldi (2005). The Ethics and Economics of Health Care. Journal of Medicine and Philosophy 30 (6):571 – 578.
Added to index2010-08-24
Total downloads10 ( #144,795 of 1,098,834 )
Recent downloads (6 months)2 ( #174,745 of 1,098,834 )
How can I increase my downloads?